Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters

When Gilead Sciences picked up Immunomedics and the breast cancer drug Trodelvy for $21 billion a couple years back, the company billed the buyout as a major expansion into oncology. Now, the California-based drugmaker is laying off more than 100 staffers based out of the former Immunomedics headquarters as it gears up for change in New Jersey.